[Use of @entity1767 in high doses in XXXX . Clinical, biochemical and pharmacokinetic study].

@entity1 @entity1246 @entity935 @entity161 @entity3829 @entity1767
The effect of high doses of @entity1767 on the clinical status, plasma neuroleptic and prolactin concentrations as well as on CSF HVA and @entity1246 levels was investigated in 3 paranoid @entity161 @entity1 over a 6 weeks period. When the study was initiated @entity1 had been on @entity1767 (10 mg a day) for 4-10 weeks. Oral doses were increased at weekly intervals from 10 (day 0) to 100 (day 7) and 200 (days 14 to 28) mg a day and then reduced to 100 (day 35) and 10 (day 42) mg/day. A linear relationship was observed between plasmatic levels and daily doses of @entity1767 . In neither @entity1 , the increase in @entity1767 dosage affected paranoid symptoms. Neurological side effects were slightly increased in 2 cases and moderately reduced in one case. Prolactin plasma levels, already high at the onset of the study rose when increasing the dose to 100 mg a day but did not increase further despite increment in the @entity1767 dosage. CSF levels of @entity3829 and @entity1246 rose from day 0 to day 7 but were back to the initial values on day 28 in 2 @entity1 and were decreased from day 0 to day 28 in one @entity1 . For the 3 @entity1 a close correlation was observed between changes in CSF HVA and @entity1246 levels. It is concluded that high doses of @entity1767 , although causing biochemical changes compatible with the occurrence of @entity935 target cell supersensitivity, do not lead to any clinical improvement in the 3 studied @entity161 @entity1 .
